Optimi is developing a sophisticated mushroom brand that focuses on the health and wellness markets. With a vertically integrated approach, Optimi intends to cultivate, extract, process and distribute high-quality functional mushroom products at its two facilities comprising a total of 20,000 square feet nearing completion in Princeton, British Columbia.
To fully investigate the science of mushrooms, the Company has received a research exemption under Health Canada Food and Drug Regulations (FDR) for the use of Psilocybin and Psilocin for scientific purposes via its wholly-owned subsidiary Optimi Labs Inc. Optimi has also applied for a dealer’s license under Canada’s Narcotic Control Regulations governing possession, distribution, sale, laboratory analysis of and research and development of Psilocybin and Psilocin formulations.
Stock Performance
Optimi Health Corp. News 80 articles
- Optimi Health completes third commercial psilocybin export to Australia
- Optimi Health completes first psilocybin export to the United Kingdom for a Phase 2 trial
- Optimi Health secures naturally derived ibogaine to expand its psychedelic drug portfolio
- Optimi Health completes commercial GMP psilocybin production run
- Optimi Health welcomes expanded Australian Authorized Prescriber framework for psilocybin and MDMA
- Optimi Health closes oversubscribed US$15M offering and uplists to Nasdaq
- Optimi Health launches ibogaine initiative after U.S. executive order
- Optimi Health completes first 2026 production run of MDMA and psilocybin capsules
- Optimi Health selected to supply MDMA for MAPS Israel's 168-patient PTSD trial
- Optimi Health Corp. Obtains U.S. FDA Drug Establishment Registration
- Optimi Health Completes Largest-to-Date MDMA Export to Australia for PTSD Therapy
- Optimi Health Obtains U.S. FDA Drug Establishment Registration
- Optimi Health Provides Corporate Update
- Optimi Health Completes Largest MDMA Capsule Batch to Date, Expands Stability Program
- Optimi Health Announces Closing of Non-Brokered Private Placement and Debt Settlement
- Optimi Health Reports First Patients Dosed in Landmark Natural Psilocybin Study in New Zealand
- Optimi Health Completes Second MDMA Shipment to Australia and Expands 2025 Production Forecast to Support Over 5,000 Patients Globally
- Optimi Health to Supply GMP-Certified Psilocybin for Psyence Biomed’s Phase IIb Palliative Care Trial
- Psyence Biomed Executes Binding Agreements with Optimi Health Corp.
- Optimi Health Announces First PTSD Patients Treated with MDMA Capsules in Australia
- Optimi Health Announces Leadership Transition
- Optimi Health & ATMA Receive No Objection Letter from Health Canada for Phase 2 Clinical Trial
- Optimi Health Completes Inaugural Export of MDMA Capsules to Australia for PTSD Treatment
- Optimi Health and Psyence Biomedical Sign Non-Binding Letter of Intent to Advance Global Psilocybin Drug Development
- Optimi Health Announces Non-Brokered Private Placement
- Optimi Health to Enter Asian Market with PsiloThai Collaboration on Psilocybin Research
- Optimi Health and Mind Medicine Australia Launch OptiMed Prescriber Portal for Australian Psychiatrists
- Health Canada Issues Three Export Permits to Optimi to Supply Patients Under Australia’s Authorised Prescriber Scheme
- Optimi Health Completes First International Shipment of MDMA to Israel and Secures CBSA Exporters Authorization ID
- Optimi Health Awarded Drug Establishment Licence From Health Canada
- Optimi Health Announces Closing of Fully Subscribed $1,500,000 Financing
- Optimi Health Secures Import Permit from Mind Medicine Australia for MDMA and Psilocybin Capsules
- Optimi Health, ATMA Sign Letter of Intent To Advance Phase II Clinical Trial Group and Individual Administration Protocol For Major Depressive Disorder
- Optimi Health Receives Certificate of Analysis For MDMA 40mg and 60mg GMP Capsules
- Optimi Health Provides Corporate Update
- Optimi Health Receives Export Permit from Health Canada to Ship MDMA To Tel Aviv University’s Institute for Psychedelic Research
- Optimi Health and Kwantlen Polytechnic University Applied Genomics Centre Partner to Advance Mushroom Science and Research
- Optimi Health Achieves Milestone: Completes In-House Production of MDMA Active Pharmaceutical Ingredient (API)
- Optimi Health Confirms Presenting Sponsorship at the 4th Annual Psychedelic Therapeutics and Drug Development Conference
- Optimi Health to Supply MDMA for Psychedelic Research at Tel Aviv University
Showing the 40 most recent of 80 articles.